FDA conditionally approves drug for canine neuropathic painMay 13, 2026Liavium-CA1 is indicated for the management of pain and clinical signs associated with Chiari-like malformation and syringomyelia in dogs. The drug, with the active ingredient pregabalin, reduces the release of neurotransmitters that send pain signals in the spinal cord.
SPONSORED CONTENTTake Control With ProHeart 12 (moxidectin)One dose offers year-long protection with a single injection, putting compliance in your hands. + Learn more
